MedTrace Logo

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

NCT02575560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-02-14

No results posted yet for this study

Summary

EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.

Conditions

  • EGFR-TKI Resistant Mutation

Interventions

OTHER

history data

history data of PFS after 1st line or second line theray

Sponsors & Collaborators

  • Qingdao Central Hospital

    lead OTHER

Principal Investigators

  • ketao lan · Qingdao Central Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2017-09-30
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02575560 on ClinicalTrials.gov